BioNano Genomics Inc vs Marriott International Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Marriott International Inc trades at $368.59 (market cap $95.77B). The key difference: Marriott International Inc is far larger — about 7255.3× BioNano Genomics Inc's market cap, and Marriott International Inc pays a 0.8% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MAR | |
|---|---|---|
Market Cap | $13.20M | $95.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $402.54 |
52-Week Low | $1.09 | $255.35 |
Enterprise Value | $15.81M | $112.72B |
Dividend Yield | — | 0.8% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Marriott International (MAR) trades at $362.87, down 3.52% today, with a bearish technical signal and mixed earnings history. The company maintains strong revenue growth, reaching $26.19B in 2025, and a net income margin of 9.72%. Recent developments include the launch of Ask Bonvoy AI and expansion to 10,000 properties, though debt levels have risen to 58.83% of assets. Analyst consensus is a $387.33 price target with 44% buy ratings.
The outlook is cautiously optimistic given solid fundamentals and strategic initiatives, but high valuation ratios and increasing leverage pose risks. Near-term performance hinges on Q2 2026 earnings due August 3, 2026, with investor focus on debt management and travel demand sustainability amid economic uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →